E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice
View/ Open
Author
Li, Zhenzhen
Ye, Zhou
Zhang, Xiaolong
Zhang, Qing
Fan, Dongmei
Zhang, Yanjun
Yuan, Xiangfei
Li, Zongfang
Xiong, Dongsheng
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.18632/oncotarget.10122Metadata
Show full item recordCitation
Li, Zhenzhen, Zhou Ye, Xiaolong Zhang, Qing Zhang, Dongmei Fan, Yanjun Zhang, Hongbo R. Luo, Xiangfei Yuan, Zongfang Li, and Dongsheng Xiong. 2016. “E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.” Oncotarget 7 (32): 51815-51828. doi:10.18632/oncotarget.10122. http://dx.doi.org/10.18632/oncotarget.10122.Abstract
Gene therapy is an attractive approach for hepatocellular carcinoma (HCC) patients. Nevertheless, efficient transgene delivery remains a challenge. In this study, we explored a new targeted system based on human umbilical cord-derived mesenchymal stem cells (HUMSCs), which were engineered to deliver adenovirus to tumor sites, and to replicate and assemble into new adenovirus against HCC. Our results showed that HUMSCs infected by Ad-hTERTp-IL24 followed by LentiR.E1A infection could specifically migrate to HepG2 tumor cells and support adenoviral replication in vitro and in vivo 36 h after LentiR.E1A infection. Ad-hTERTp-IL24 specifically inhibited HepG2 cells growth, and this inhibitory effect was enhanced by low doses of 5-fluorouracil (5-Fu), because the expression levels of coxsackie adenovirus receptor (CAR) and integrin ανβ3 on tumor cells were significantly increased, causing higher viral uptake. Compared with the no treatment groups, Ad-hTERTp-IL24 and LentiR.E1A co-loaded HUMSCs exhibited significant anti-tumor activity in vivo, particularly in combination with low doses of 5-Fu. In summary, this study provides a promising targeted gene therapeutic strategy dependent on the tumor tropism of HUMSCs, to improve the outcome of virotherapy for tumor patients especially those with metastatic diseases.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239516/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370956
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)